Workflow for the development, validation, and application of the HSCT-64 risk framework. (IMAGE)
Caption
A combination of four publicly available pediatric acute myeloid leukemia (pAML) cohorts was used as the discovery set to develop the HSCT-64 framework, which includes two parallel models: aHSCT-64 for allo-HSCT cases and nHSCT-64 for non-HSCT cases. Two independent pAML cohorts were employed for external validation. By comparing risk rankings generated by aHSCT-64 and nHSCT-64 in the independent cohort (n = 233), we identified the HSCT-benefiting subgroup (blue dots) as patients with a decreased risk rank from nHSCT-64 to aHSCT-64 and the HSCT-nonbenefiting subgroup (red dots) as those with an increased risk rank.
Credit
Yance Feng, Yali Shen, Ke Huang, Qian Li, Yu Tao, Rongqiu Liu, Liping Zhan, Hua Yang, Yang Xun , Yichao Xu, Wenli Tang, Binjun Xiong, Hui Shi, Liting Cheng, Li Wei, Hua You
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND